1932

Abstract

The term prediabetes describes blood glucose levels above the normal range but below the threshold to diagnose type 2 diabetes. Several population health initiatives encourage a test and treat approach for prediabetes. In this approach, screening and identification of individuals with prediabetes should be followed by prompt referral to structured lifestyle modification programs or pharmacologic interventions that have been shown to prevent or delay the progression to type 2 diabetes in clinical trials. Here we provide a critical review of evidence for this test and treat approach by examining health outcomes associated with prediabetes and the availability and effectiveness of lifestyle modification approaches that target prediabetes. We also describe current limitations to the reach and uptake of evidence-based treatment options for prediabetes. Finally, we highlight lessons learned from identifying and labeling other preconditions to consider challenges and opportunities that may arise with increasing awareness of prediabetes as part of routine preventive care.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-publhealth-060222-023417
2024-05-20
2024-06-25
Loading full text...

Full text loading...

/deliver/fulltext/publhealth/45/1/annurev-publhealth-060222-023417.html?itemId=/content/journals/10.1146/annurev-publhealth-060222-023417&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Abdul-Ghani MA, Tripathy D, DeFronzo RA. 2006.. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. . Diabetes Care 29:(5):113039
    [Crossref] [Google Scholar]
  2. 2.
    Ali MK, McKeever Bullard K, Imperatore G, Benoit SR, Rolka DB, et al. 2019.. Reach and use of diabetes prevention services in the United States, 2016–2017. . JAMA Netw. Open 2:(5):e193160
    [Crossref] [Google Scholar]
  3. 3.
    Alva ML, Chakkalakal RJ, Moin T, Galaviz KI. 2022.. The diabetes prevention gap and opportunities to increase participation in effective interventions. . Health Aff. 41:(7):97179
    [Crossref] [Google Scholar]
  4. 4.
    Am. Diabetes Assoc. 2021.. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2021. . Diabetes Care 44:(Suppl. 1):S1533
    [Google Scholar]
  5. 5.
    Am. Diabetes Assoc. Prof. Pract. Comm. 2022.. 3. Prevention or delay of type 2 diabetes and associated comorbidities: Standards of Medical Care in Diabetes—2022. . Diabetes Care 45:(Suppl. 1):S3945
    [Google Scholar]
  6. 6.
    Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, et al. 2017.. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. . Lancet Diabetes Endocrinol. 5:(8):58596
    [Crossref] [Google Scholar]
  7. 7.
    Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, et al. 2011.. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. . Diabetologia 54:(12):302227
    [Crossref] [Google Scholar]
  8. 8.
    Balk EM, Earley A, Raman G, Avendano EA, Pittas AG, Remington PL. 2015.. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. . Ann. Intern. Med. 163:(6):43751
    [Crossref] [Google Scholar]
  9. 9.
    Barger SD, Muldoon MF. 2006.. Hypertension labelling was associated with poorer self-rated health in the Third US National Health and Nutrition Examination Survey. . J. Hum. Hypertens. 20:(2):11723
    [Crossref] [Google Scholar]
  10. 10.
    Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T. 2017.. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. . BMJ 356::i6538
    [Crossref] [Google Scholar]
  11. 11.
    Baucom KJW, Pershing ML, Dwenger KM, Karasawa M, Cohan JN, Ozanne EM. 2021.. Barriers and facilitators to enrollment and retention in the National Diabetes Prevention Program: perspectives of women and clinicians within a health system. . Womens Health Rep. 2:(1):13341
    [Google Scholar]
  12. 12.
    Blond MB, Færch K, Herder C, Ziegler D, Stehouwer CDA. 2023.. The prediabetes conundrum: striking the balance between risk and resources. . Diabetologia 66::101623
    [Crossref] [Google Scholar]
  13. 13.
    Boltri JM, Tracer H, Strogatz D, Idzik S, Schumacher P, et al. 2023.. The National Clinical Care Commission Report to Congress: leveraging federal policies and programs to prevent diabetes in people with prediabetes. . Diabetes Care 46:(2):e3950
    [Crossref] [Google Scholar]
  14. 14.
    Cai X, Zhang Y, Li M, Wu JHY, Mai L, et al. 2020.. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. . BMJ 370::m2297
    [Crossref] [Google Scholar]
  15. 15.
    Campbell MD, Sathish T, Zimmet PZ, Thankappan KR, Oldenburg B, et al. 2020.. Benefit of lifestyle-based T2DM prevention is influenced by prediabetes phenotype. . Nat. Rev. Endocrinol. 16:(7):395400
    [Crossref] [Google Scholar]
  16. 16.
    Cannon MJ, Ng BP, Lloyd K, Reynolds J, Ely EK. 2022.. Delivering the National Diabetes Prevention Program: assessment of enrollment in in-person and virtual organizations. . J. Diabetes Res. 2022::2942918
    [Crossref] [Google Scholar]
  17. 17.
    CDC (Cent. Dis. Control Prev.). 2022.. Prevalence of prediabetes among adults. . Diabetes. https://www.cdc.gov/diabetes/data/statistics-report/prevalence-of-prediabetes.html
    [Google Scholar]
  18. 18.
    CDC (Cent. Dis. Control Prev.), US Dep. Health Hum. Serv. 2022.. National Diabetes Statistics Report. Estimates of diabetes and its burden in the United States. . Diabetes. https://www.cdc.gov/diabetes/data/statistics-report/index.html
    [Google Scholar]
  19. 19.
    CDC (Cent. Dis. Control Prev.), US Dep. Health Hum. Serv. 2023.. Registry of all recognized organizations. . Diabetes Prevention Recognition Program Application. https://dprp.cdc.gov/Registry
    [Google Scholar]
  20. 20.
    Cheng YJ, Kanaya AM, Araneta MRG, Saydah SH, Kahn HS, et al. 2019.. Prevalence of diabetes by race and ethnicity in the United States, 2011–2016. . JAMA 322:(24):238998
    [Crossref] [Google Scholar]
  21. 21.
    Conlin PR, Greenlee C, Schillinger D, Lopata A, Boltri JM, et al. 2022.. The National Clinical Care Commission Report: improving federal programs that impact diabetes prevention and care. . Ann. Intern. Med. 175:(4):59497
    [Crossref] [Google Scholar]
  22. 22.
    Davidson MB. 2020.. Metformin should not be used to treat prediabetes. . Diabetes Care 43:(9):198387
    [Crossref] [Google Scholar]
  23. 23.
    Diabetes Prev. Program Res. Group. 2015.. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. . Lancet Diabetes Endocrinol. 3:(11):86675
    [Crossref] [Google Scholar]
  24. 24.
    Ekoe J-M, Goldenberg R, Katz P. 2018.. Screening for diabetes in adults. . Can. J. Diabetes 42:(Suppl. 1):S1619
    [Crossref] [Google Scholar]
  25. 25.
    ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, et al. 2023.. 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes2023. . Diabetes Care 46:(Suppl. 1):S1940
    [Crossref] [Google Scholar]
  26. 26.
    Galaviz KI, Weber MB, Straus A, Haw JS, Narayan KMV, Ali MK. 2018.. Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. . Diabetes Care 41:(7):152634
    [Crossref] [Google Scholar]
  27. 27.
    Galaviz KI, Weber MB, Suvada KB, Gujral UP, Wei J, et al. 2022.. Interventions for reversing prediabetes: a systematic review and meta-analysis. . Am. J. Prev. Med. 62:(4):61425
    [Crossref] [Google Scholar]
  28. 28.
    Gelband H, Jha P, Sankaranarayanan R, Horton S, eds. 2015.. Disease Control Priorities: Vol. 3: Cancer. Washington, DC:: World Bank. , 3rd ed..
    [Google Scholar]
  29. 29.
    Gong Q, Zhang P, Wang J, Ma J, An Y, et al. 2019.. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. . Lancet Diabetes Endocrinol. 7:(6):45261
    [Crossref] [Google Scholar]
  30. 30.
    Gujral UP, Jagannathan R, He S, Huang M, Staimez LR, et al. 2021.. Association between varying cut-points of intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a systematic review and meta-analysis. . BMJ Open Diabetes Res. Care 9:(1):e001776
    [Crossref] [Google Scholar]
  31. 31.
    Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, et al. 2015.. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. . Endocr. Pract. 21:(Suppl. 1):187
    [Crossref] [Google Scholar]
  32. 32.
    Harrison CR, Phimphasone-Brady P, DiOrio B, Raghuanath SG, Bright R, et al. 2020.. Barriers and facilitators of National Diabetes Prevention Program engagement among women of childbearing age: a qualitative study. . Diabetes Educ. 46:(3):27988
    [Crossref] [Google Scholar]
  33. 33.
    Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, et al. 2017.. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. . JAMA Intern Med. 177:(12):180817
    [Crossref] [Google Scholar]
  34. 34.
    He S, Wang J, Shen X, Qian X, An Y, et al. 2022.. Cancer and its predictors in Chinese adults with newly diagnosed diabetes and impaired glucose tolerance (IGT): a 30-year follow-up of the Da Qing IGT and Diabetes Study. . Br. J. Cancer 127:(1):1028
    [Crossref] [Google Scholar]
  35. 35.
    Herman WH. 2023.. Prediabetes diagnosis and management. . JAMA 329:(14):115759
    [Crossref] [Google Scholar]
  36. 36.
    Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, et al. 2007.. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. . Diabetes Care 30:(11):287479
    [Crossref] [Google Scholar]
  37. 37.
    Hoerger TJ, Jacobs S, Romaire M, Allaire B, Neuwahl S, et al. 2022.. Evaluation of the Medicare Diabetes Prevention Program: second evaluation report. Rep., RTI Int. , Research Triangle Park, NC:. https://innovation.cms.gov/data-and-reports/2022/mdpp-2ndannevalrpt
    [Google Scholar]
  38. 38.
    Int. Diabetes Fed. 2021.. IDF Diabetes Atlas 2021. Brussels, Belg.:: Int. Diabetes Fed. , 10th ed.. https://diabetesatlas.org/atlas/tenth-edition/
    [Google Scholar]
  39. 39.
    Int. Expert Comm. 2009.. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. . Diabetes Care 32:(7):132734
    [Crossref] [Google Scholar]
  40. 40.
    Jose J, Thomas N. 2018.. How should one tackle prediabetes in India?. Indian J. Med. Res. 148:(6):67576
    [Crossref] [Google Scholar]
  41. 41.
    Kalra S, Singal A, Lathia T. 2021.. What's in a name? Redefining type 2 diabetes remission. . Diabetes Ther. 12:(3):64754
    [Crossref] [Google Scholar]
  42. 42.
    Kandula NR, Moran MR, Tang JW, O'Brien MJ. 2018.. Preventing diabetes in primary care: providers’ perspectives about diagnosing and treating prediabetes. . Clin. Diabetes 36:(1):5966
    [Crossref] [Google Scholar]
  43. 43.
    Knowles S, Cotterill S, Coupe N, Spence M. 2019.. Referral of patients to diabetes prevention programmes from community campaigns and general practices: mixed-method evaluation using the RE-AIM framework and normalisation process theory. . BMC Health Serv. Res. 19::321
    [Crossref] [Google Scholar]
  44. 44.
    Lazo-Porras M, Bernabe-Ortiz A, Ruiz-Alejos A, Smeeth L, Gilman RH, et al. 2020.. Regression from prediabetes to normal glucose levels is more frequent than progression towards diabetes: The CRONICAS Cohort Study. . Diabetes Res. Clin. Pract. 163::107829
    [Crossref] [Google Scholar]
  45. 45.
    Magliano DJ, Boyko EJ. 2021.. What is diabetes?. See Ref. 38, chapter 1
  46. 46.
    Mainous AG 3rd, Tanner RJ, Scuderi CB, Porter M, Carek PJ. 2016.. Prediabetes screening and treatment in diabetes prevention: the impact of physician attitudes. . J. Am. Board Fam. Med. 29:(6):66371
    [Crossref] [Google Scholar]
  47. 47.
    Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R, Aging Baltim. Longitud. Stud. 2003.. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. . Diabetes 52:(6):147584
    [Crossref] [Google Scholar]
  48. 48.
    Merlotti C, Morabito A, Pontiroli AE. 2014.. Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. . Diabetes Obesity Metab. 16:(8):71927
    [Crossref] [Google Scholar]
  49. 49.
    Mousavi S, Namayandeh SM, Fallahzadeh H, Rahmanian M, Mollahosseini M. 2023.. Comparing the effectiveness of metformin with lifestyle modification for the primary prevention of type II diabetes: a systematic review and meta-analysis. . BMC Endocr. Disord. 23::198
    [Crossref] [Google Scholar]
  50. 50.
    Narayan KMV, Williamson DF. 2010.. Prevention of type 2 diabetes: risk status, clinic, and community. . J. Gen. Intern. Med. 25:(2):15457
    [Crossref] [Google Scholar]
  51. 51.
    Nhim K, Khan T, Gruss SM, Wozniak G, Kirley K, et al. 2018.. Primary care providers’ prediabetes screening, testing, and referral behaviors. . Am. J. Prev. Med. 55:(2):e3947
    [Crossref] [Google Scholar]
  52. 52.
    NHS Engl. 2022.. 2022 NHS Diabetes Prevention Programme national service specification. PR1946 , NHS Engl., Leeds, UK:. https://www.england.nhs.uk/wp-content/uploads/2016/08/Diabetes-Prevention-Programme-Framework-3-Service-Specification-October-2022.pdf
    [Google Scholar]
  53. 53.
    NICE (Natl. Inst. Health Care Excell.). 2012.. Type 2 diabetes: prevention in people at high risk. Public Health Guidel. [PH38] , NICE, Manchester, UK:. https://www.nice.org.uk/guidance/PH38/chapter/Recommendations
    [Google Scholar]
  54. 54.
    Pang B, Lian F-M, Zhao X-Y, Zhao X-M, Jin D, et al. 2017.. Prevention of type 2 diabetes with the traditional Chinese patent medicine: a systematic review and meta-analysis. . Diabetes Res. Clin. Pract. 131::24259
    [Crossref] [Google Scholar]
  55. 55.
    Park P, Simmons RK, Prevost AT, Griffin SJ. 2008.. Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice. . BMC Public Health 8:(1):350
    [Crossref] [Google Scholar]
  56. 56.
    Penn L, Rodrigues A, Haste A, Marques MM, Budig K, et al. 2018.. NHS Diabetes Prevention Programme in England: formative evaluation of the programme in early phase implementation. . BMJ Open 8:(2):e019467
    [Crossref] [Google Scholar]
  57. 57.
    Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, et al. 2012.. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. . Lancet 379:(9833):224351
    [Crossref] [Google Scholar]
  58. 58.
    Perreault L, Pan Q, Schroeder EB, Kalyani RR, Bray GA, et al. 2019.. Regression from prediabetes to normal glucose regulation and prevalence of microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). . Diabetes Care 42:(9):180915
    [Crossref] [Google Scholar]
  59. 59.
    Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, et al. 2014.. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program Outcomes Study. . Diabetes Care 37:(9):262231
    [Crossref] [Google Scholar]
  60. 60.
    Phung OJ, Baker WL, Tongbram V, Bhardwaj A, Coleman CI. 2012.. Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis. . Ann. Pharmacother. 46:(4):46976
    [Crossref] [Google Scholar]
  61. 61.
    Ramachandran A, Arun N, Shetty AS, Snehalatha C. 2010.. Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2). . Diabetes Care 33:(10):216468
    [Crossref] [Google Scholar]
  62. 62.
    Richter B, Hemmingsen B, Metzendorf M-I, Takwoingi Y. 2018.. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. . Cochrane Database Syst Rev. 10:(10):012661
    [Google Scholar]
  63. 63.
    Roberts S, Barry E, Craig D, Airoldi M, Bevan G, Greenhalgh T. 2017.. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. . BMJ Open 7:(11):e017184
    [Crossref] [Google Scholar]
  64. 64.
    Rooney MR, Rawlings AM, Pankow JS, Echouffo Tcheugui JB, Coresh J, et al. 2021.. Risk of progression to diabetes among older adults with prediabetes. . JAMA Intern. Med. 181:(4):51119
    [Crossref] [Google Scholar]
  65. 65.
    Rose G. 2001.. Sick individuals and sick populations. . Int. J. Epidemiol. 30:(3):42732
    [Crossref] [Google Scholar]
  66. 66.
    Saito T, Watanabe M, Nishida J, Izumi T, Omura M, et al. 2011.. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. . Arch. Intern. Med. 171:(15):135260
    [Crossref] [Google Scholar]
  67. 67.
    Sathish T. 2023.. Comment on Rooney et al. Global Prevalence of Prediabetes. Diabetes Care 2023;46:1388–1394. . Diabetes Care 46:(12):e219
    [Crossref] [Google Scholar]
  68. 68.
    Sathish T, Khunti K, Narayan KMV, Mohan V, Davies MJ, et al. 2023.. Effect of conventional lifestyle interventions on type 2 diabetes incidence by glucose-defined prediabetes phenotype: an individual participant data meta-analysis of randomized controlled trials. . Diabetes Care 46:(11):19037
    [Crossref] [Google Scholar]
  69. 69.
    Sathish T, Tapp RJ, Shaw JE. 2021.. Do lifestyle interventions reduce diabetes incidence in people with isolated impaired fasting glucose?. Diabetes Obes. Metab. 23:(12):282728
    [Crossref] [Google Scholar]
  70. 70.
    Shen XX, Wang JP, Chen YY, An YL, Gong QH, et al. 2019.. Subjects with impaired glucose tolerance returned to normal glucose status for six years had lower long-term risk of diabetes: 20 years follow up of Daqing diabetes prevention study. . Zhonghua Nei Ke Za Zhi 58:(5):37276
    [Google Scholar]
  71. 71.
    Sheng Z, Cao J-Y, Pang Y-C, Xu H-C, Chen J-W, et al. 2019.. Effects of lifestyle modification and anti-diabetic medicine on prediabetes progress: a systematic review and meta-analysis. . Front. Endocrinol. 10::455
    [Crossref] [Google Scholar]
  72. 72.
    Shortsleeve C. 2019.. What to do if you have these medical preconditions. . AARP, Aug. 13. https://www.aarp.org/health/conditions-treatments/info-2019/preconditions.html
    [Google Scholar]
  73. 73.
    Siu AL. 2015.. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. . Ann. Intern. Med. 163:(10):77886
    [Crossref] [Google Scholar]
  74. 74.
    Siu AL, Bibbins-Domingo K, Grossman DC, LeFevre ML. 2016.. Convergence and divergence around breast cancer screening. . Ann. Intern. Med. 164:(4):3012
    [Crossref] [Google Scholar]
  75. 75.
    Spruill TM, Feltheimer SD, Harlapur M, Schwartz JE, Ogedegbe G, et al. 2013.. Are there consequences of labeling patients with prehypertension? An experimental study of effects on blood pressure and quality of life. . J. Psychosom. Res. 74:(5):43338
    [Crossref] [Google Scholar]
  76. 76.
    Srivastava A, Mirza TM, Sharan S. 2023.. Prehypertension. . In StatPearls. Treasure Island, FL:: StatPearls Publ.
    [Google Scholar]
  77. 77.
    Tseng E, Greer RC, O'Rourke P, Yeh H-C, McGuire MM, et al. 2019.. National survey of primary care physicians’ knowledge, practices, and perceptions of prediabetes. . J. Gen. Intern. Med. 34:(11):247581
    [Crossref] [Google Scholar]
  78. 78.
    Twohig H, Hodges V, Hobbis C, Mitchell C. 2019.. Response to diagnosis of pre-diabetes in socioeconomically deprived areas: a qualitative study. . BJGP Open 3:(3):bjgpopen19X101661
    [Crossref] [Google Scholar]
  79. 79.
    US Prev. Serv. Task Force. 2021.. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. . JAMA 326:(8):73643
    [Crossref] [Google Scholar]
  80. 80.
    US Prev. Serv. Task Force. 2023.. Breast cancer: screening. Draft Recomm. Statement, May 9 , US Prev. Serv. Task Force, Rockville, MD:. https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/breast-cancer-screening-adults
    [Google Scholar]
  81. 81.
    Uusitupa M, Khan TA, Viguiliouk E, Kahleova H, Rivellese AA, et al. 2019.. Prevention of type 2 diabetes by lifestyle changes: a systematic review and meta-analysis. . Nutrients 11:(11):2611
    [Crossref] [Google Scholar]
  82. 82.
    Viera AJ, Lingley K, Esserman D. 2010.. Effects of labeling patients as prehypertensive. . J. Am. Board Fam. Med. 23:(5):57183
    [Crossref] [Google Scholar]
  83. 83.
    Wallace AS, Rooney MR, Fang M, Echouffo-Tcheugui JB, Grams M, Selvin E. 2023.. Natural history of prediabetes and long-term risk of clinical outcomes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. . Diabetes Care 46:(2):e6768
    [Crossref] [Google Scholar]
  84. 84.
    Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, et al. 2017.. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. . Lancet Diabetes Endocrinol. 5:(1):3442
    [Crossref] [Google Scholar]
  85. 85.
    Weber MB, Ranjani H, Staimez LR, Anjana RM, Ali MK, et al. 2016.. The stepwise approach to diabetes prevention: results from the D-CLIP randomized controlled trial. . Diabetes Care 39:(10):176067
    [Crossref] [Google Scholar]
  86. 86.
    Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, et al. 2018.. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. . J. Am. Coll. Cardiol. 71:(19):e127248
    [Google Scholar]
  87. 87.
    WHO (World Health Organ.), Int. Diabetes Fed. 2006.. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Rep. , WHO, Geneva:. https://apps.who.int/iris/bitstream/handle/10665/43588/9241594934_eng.pdf
    [Google Scholar]
  88. 88.
    Wilson JMG, Jungner G. 1968.. Principles and Practice of Screening for Disease. Geneva:: World Health Organ.
    [Google Scholar]
  89. 89.
    Yamaoka K, Nemoto A, Tango T. 2019.. Comparison of the effectiveness of lifestyle modification with other treatments on the incidence of type 2 diabetes in people at high risk: a network meta-analysis. . Nutrients 11:(6):1373
    [Crossref] [Google Scholar]
  90. 90.
    Yip WCY, Sequeira IR, Plank LD, Poppitt SD. 2017.. Prevalence of pre-diabetes across ethnicities: a review of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) for classification of dysglycaemia. . Nutrients 9:(11):1273
    [Crossref] [Google Scholar]
  91. 91.
    Zhang Y, Tan H, Tang J, Li J, Chong W, et al. 2020.. Effects of vitamin D supplementation on prevention of type 2 diabetes in patients with prediabetes: a systematic review and meta-analysis. . Diabetes Care 43:(7):165058
    [Crossref] [Google Scholar]
  92. 92.
    Zhou X, Siegel KR, Ng BP, Jawanda S, Proia KK, et al. 2020.. Cost-effectiveness of diabetes prevention interventions targeting high-risk individuals and whole populations: a systematic review. . Diabetes Care 43:(7):1593616
    [Crossref] [Google Scholar]
/content/journals/10.1146/annurev-publhealth-060222-023417
Loading
/content/journals/10.1146/annurev-publhealth-060222-023417
Loading

Data & Media loading...

Supplemental Material

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error